BOSTON--(BUSINESS WIRE)--Monopteros Therapeutics Inc. (“Monopteros”), a clinical-stage biotechnology company developing MPT-0118, a first-in-class MALT1 inhibitor for the treatment of solid tumors, ...
Lockheed Martin‘s (NYSE: LMT) aeronautics segment will develop a common reprogramming tool for the F-35 program under a $111.1 million contract modification awarded by the U.S. Navy. The business will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback